Yes, levodopa (L-dopa) is still used, and it remains the single most effective medication for managing the motor symptoms of Parkinson’s disease. More than 50 years after its introduction, no drug has surpassed it for reducing tremor, stiffness, and slowness of movement. What has changed dramatically is how it’s delivered: today’s patients have access to extended-release tablets, inhaled rescue doses, intestinal pumps, and subcutaneous infusions that didn’t exist a decade ago.
Why Levodopa Still Works Better Than Alternatives
Parkinson’s disease is driven by a shortage of dopamine in the brain. Dopamine itself can’t cross from the bloodstream into the brain, but levodopa can. Once inside the brain, it converts to dopamine and replenishes what’s been lost. It’s a simple, elegant workaround, and it produces stronger motor improvement than any competing drug class.
A network meta-analysis of nine randomized trials covering over 2,100 patients found that levodopa ranked first for improving both daily activity scores and motor examination scores, outperforming all tested dopamine agonists. The tradeoff is a higher likelihood of involuntary movements called dyskinesias over time. Population data from Olmsted County found that about 30% of patients develop dyskinesia of any severity within five years, rising to 59% after ten years of treatment.
Dopamine agonists (a different drug class that mimics dopamine rather than converting into it) carry a lower dyskinesia risk, which is why the American Academy of Neurology’s 2021 guidelines allow their use as an alternative first treatment in patients with mild symptoms, particularly younger, thinner, and female patients, who face a greater dyskinesia risk. But for most people, levodopa is where treatment begins or quickly arrives.
How It’s Taken Today
Almost no one takes plain levodopa anymore. It’s nearly always combined with carbidopa, a companion drug that blocks levodopa from converting to dopamine outside the brain. Without carbidopa, most of the levodopa you swallow gets used up in your body before it ever reaches your brain, causing nausea and other side effects. With carbidopa on board, more levodopa gets where it needs to go.
The standard form is an oral tablet (carbidopa/levodopa), available in both immediate-release and extended-release versions. Most people start with immediate-release tablets taken several times a day. Extended-release formulations spread the drug out over a longer window, which can smooth out the “wearing off” periods when a dose fades before the next one kicks in.
Newer Delivery Methods for Advanced Disease
As Parkinson’s progresses, oral tablets become harder to manage. The stomach empties more slowly, absorption becomes unpredictable, and patients can swing between “on” periods (when the medication is working) and “off” periods (when symptoms return). Several newer delivery systems address this directly.
Inhaled Levodopa
Inbrija is an inhaled form of levodopa approved specifically as a rescue treatment for off episodes. When you feel symptoms returning between your regular doses, you inhale the contents of two small capsules (84 mg total) through a handheld device. It can be used up to five times a day. Because it’s absorbed through the lungs rather than the gut, it bypasses the slow, unreliable digestion that causes many off episodes in the first place.
Intestinal Gel Infusion
For people with severe motor fluctuations (defined as at least three hours of daily off time despite optimized oral medications), a carbidopa/levodopa gel can be delivered continuously through a small tube placed directly into the upper intestine. A portable pump worn on the body provides a steady stream of medication throughout the day. In a 54-week study, patients on this system saw their daily off time drop by an average of 4.4 hours (a 65% reduction) and gained nearly 5 extra hours of good movement time per day. Morning onset improved too: the average wait from waking to feeling “on” shrank from 108 minutes at baseline to about 51 minutes by week 54.
Subcutaneous Infusion
A newer option, foslevodopa-foscarbidopa (sold as Vyalev or Produodopa), delivers levodopa and carbidopa continuously under the skin via a small pump. It avoids the need for a surgically placed intestinal tube, making it less invasive than the gel system while still providing round-the-clock drug delivery. It was approved after a Phase 3 trial showed meaningful reductions in off time compared to oral treatment.
Managing Side Effects Over Time
The most talked-about long-term complication of levodopa is dyskinesia: involuntary, often flowing or writhing movements that appear when drug levels peak. Dyskinesia tends to emerge after years of use, not immediately. Early in treatment, the brain can buffer fluctuations in dopamine levels. As more dopamine-producing cells are lost to Parkinson’s itself, the brain becomes increasingly sensitive to each dose, and the therapeutic window between “too little” (off) and “too much” (dyskinesia) narrows.
Wearing off is the other common challenge. Doses that once lasted four or five hours may start fading after two or three. This is a normal part of disease progression, not a sign that levodopa has stopped working. Adjustments like smaller, more frequent doses, adding extended-release formulations, or switching to a continuous delivery system can recapture much of the lost benefit.
Diet and Timing Tips That Matter
Levodopa competes with dietary protein for absorption. Both levodopa and the amino acids from protein use the same transport system to cross from the gut into the bloodstream and from the bloodstream into the brain. Eating a high-protein meal alongside your dose can reduce peak drug levels by about 30% on average.
The standard advice is to take levodopa on an empty stomach, 30 minutes before or two hours after a meal. If nausea is a problem, a small carbohydrate snack like crackers, toast, or applesauce can help without significantly interfering with absorption. Some people with noticeable motor fluctuations benefit from a protein redistribution diet, where protein intake at breakfast and lunch is kept low and the bulk of daily protein is eaten at dinner. Total protein should stay at a healthy level (at least 0.8 grams per kilogram of body weight per day) to avoid muscle loss, which is already a concern in Parkinson’s.
Why It Hasn’t Been Replaced
Every few years, a new drug class generates hope that it might overtake levodopa. Dopamine agonists, enzyme inhibitors, and various combination therapies have all earned a place in Parkinson’s management, but none match levodopa’s raw effectiveness at controlling motor symptoms. The real progress has been in refining how levodopa is delivered: getting it into the brain more steadily, more reliably, and with fewer peaks and valleys. That trajectory suggests levodopa won’t be replaced anytime soon. It will simply be delivered in smarter ways.